AI reads CT scans to predict stomach Cancer's return
NCT ID NCT07683195
First seen Jul 06, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This study explores whether artificial intelligence can predict if stomach cancer will come back within a year after surgery. Researchers will analyze CT scans and clinical data from 900 patients with locally advanced gastric cancer. The goal is to build a model that helps doctors identify high-risk patients earlier.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this AI model could help doctors identify patients at high risk of cancer returning soon after surgery, allowing for closer monitoring or earlier treatment.
- What could go wrong
- This is an observational study using existing data, not a treatment trial. The AI model may not be accurate enough for real-world use, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 900 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2020
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients with locally advanced gastric cancer
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. pathology diagnosis of LAGC (pT2NxM0-pT4NxM0); 2. radical gastrectomy with D2 lymph node dissection (\>15 lymph nodes); 3. available clinicopathological data; 4. patients underwent contrast-enhanced abdominal CT scans within 4 weeks before surgery. Exclusion Criteria: 1. preoperative treatment for LAGC (radiotherapy, chemotherapy, or systemic therapy); 2. previous malignancies; 3. unsatisfactory gastric distention or inability to identify the primary tumor; 4. image artifacts.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastric cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
QianfoshanH
Jinan, Shandong, 250014, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shrink advanced solid tumors?
- Can a pill replace chemo for stomach cancer in the elderly?
- Can a new drug shrink tumors that resist standard care?
- Can an oral drug R01 fight advanced lung, stomach, and esophageal cancers?
- Can a new drug duo shrink Hard-to-Treat tumors?
- Can custom vitamin pills fix nutrient gaps after stomach or esophageal cancer surgery?